Genentech is a biotechnology company headquartered in San Francisco. The company discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions, including cancer, strokes, and immune system disorders. Genentech has a number of products in the research pipeline for Alzheimer’s disease. Genentech has two candidate disease-modifying therapies in late-stage development called Crenezumab and Gantenerumab. Both are in Phase 3 studies. Additionally, Genentech has another molecule in Phase 1 that has yet to be named. For more information: http://www.genentech.com.